For Immediate Release
Does Stem Cell Therapy Offer the Best Hope for Neurodegenerative Diseases?
New Rochelle, NY, October 24, 2017—As the brain has limited capability for self-repair or regeneration, stem cells may represent the best therapeutic approach for counteracting damage to or degeneration of brain tissue caused by injury, aging, or disease. Although preclinical testing of stem cell therapies has shown promise, results achieved in animals are not necessarily indicative of what will occur in patients, and clinical studies in humans have been limited in size and number. The potential value of stem cells and emerging therapeutic agents in neurodegenerative diseases are the focus of an article published in Rejuvenation Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Rejuvenation Research website until November 24, 2017.
About the Journal
Rejuvenation Research is the premier peer-reviewed journal providing cutting-edge research on rejuvenation therapies in the laboratory and clinic. Led by Editor-in-Chief Aubrey D.N.J. de Grey, PhD, SENS Foundation, Mountain View, CA, the Journal provides key explorations and advances that may ultimately contribute to slowing or reversing the aging process, and covers topics such as cardiovascular aging, DNA damage and repair, cloning, and cell immortalization and senescence. Rejuvenation Research is the Official Journal of the European Society of Preventive, Regenerative and Anti-Aging Medicine (ESAAM) and the World Federation & World Virtual Institute of Preventive & Regenerative Medicine (PYRAMED). Complete tables of content and a sample issue may be viewed on the Rejuvenation Research website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Cellular Reprogramming, DNA and Cell Biology, and Human Gene Therapy. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101